A comparison of loco-regional relapse pattern in HPV positive vs negative oropharyngeal cancers following radiotherapy; relation to pretreatment FDG-PET and radiotherapy target volumes

References

• DiGiulio S. Oropharyngeal cancer now most common head & neck cancer. Oncol Times. 2014;36(22):96–97. doi:10.1097/01.COT.0000457364.58827.33.
   Google Scholar
• Danish Head and Neck Cancer Group. Årsrapport 2020 for den kliniske kvalitetsdatabase DAHANCA. Danish Head and Neck Cancer Group (DK); 2020.
   Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–4301. doi:10.1200/JCO.2011.36.4596.
   PubMed Web of Science ®Google Scholar
• Zamani M, Grønhøj C, Jensen DH, et al. The current epidemic of HPV-associated oropharyngeal cancer an 18-year Danish population-based study with 2,169 patients the current epidemic of HPV-associated oropharyngeal cancer: an 18-year Danish population-based study with 2,169 patients. Eur J Cancer. 2020;134:52–59. doi:10.1016/j.ejca.2020.04.027.
   PubMed Web of Science ®Google Scholar
• O’Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–451. doi:10.1016/S1470-2045(15)00560-4.
   PubMed Web of Science ®Google Scholar
• Lydiatt WM, Patel SG, O’Sullivan B, et al. Head and neck cancers-major changes in the American Joint Committe on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67(2):122–137. doi:10.3322/caac.21389.
   PubMed Web of Science ®Google Scholar
• Monika Studer G, Glanzmann C. Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer: in regard to Schoenfeld et al. (Int J Radiat Oncol Biol Phys 2008;71:377–385). Int J Radiat Oncol Biol Phys. 2008;72(4):1271–1272. doi:10.1016/j.ijrobp.2008.07.022.
   Web of Science ®Google Scholar
• Johansen S, Norman MH, Dale E, et al. Patterns of local-regional recurrence after conformal and intensity-modulated radiotherapy for head and neck cancer. Radiat Oncol. 2017;12(1):87. doi:10.1186/s13014-017-0829-5.
   PubMedGoogle Scholar
• Due AK, Vogelius IR, Aznar MC, et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol. 2014;111(3):360–365. doi:10.1016/j.radonc.2014.06.001.
   PubMed Web of Science ®Google Scholar
• Soto DE, Kessler ML, Piert M, et al. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head & neck cancers. Radiother Oncol. 2008;89(1):13–18. doi:10.1016/j.radonc.2008.05.021.
   PubMed Web of Science ®Google Scholar
• Mohamed ASR, Cardenas CE, Garden AS, et al. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Radiother Oncol. 2017;124(2):248–255. doi:10.1016/j.radonc.2017.07.017.
   PubMed Web of Science ®Google Scholar
• Vogelius IR, Håkansson K, Due AK, et al. Failure-probability driven dose painting. Med Phys. 2013;40(8):081717. doi:10.1118/1.4816308.
   PubMed Web of Science ®Google Scholar
• Patel RR, Ludmir EB, Augustyn A, et al. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: a systematic review of prospective trials. Oral Oncol. 2020;103:104608. doi:10.1016/j.oraloncology.2020.104608.
   PubMed Web of Science ®Google Scholar
• Liu C, Mann D, Sinha UK, et al. The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg. 2018;47(1):59. doi:10.1186/s40463-018-0302-y.
   PubMedGoogle Scholar
• Kjems J, Zukauskaite R, Johansen J, et al. Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study. Acta Oncol. 2021;60(11):1472–1480. doi:10.1080/0284186X.2021.1959056.
   PubMed Web of Science ®Google Scholar
• Danish Head and Neck Cancer Group. Radiotherapy guidelines 2020. 2020. Available from: https://www.dahanca.dk/uploads/TilFagfolk/Guideline/GUID_DAHANCA_Radiotherapy_guidelines_2020.pdf
   Google Scholar
• Nøhr A, Gram SB, Charabi B, et al. PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2019;276(10):2895–2902. doi:10.1007/s00405-019-05550-1.
   PubMed Web of Science ®Google Scholar
• Due AK, Korreman S, Bentzen SM, et al. Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes. Acta Oncol. 2010;49(7):984–990. doi:10.3109/0284186X.2010.498833.
   PubMed Web of Science ®Google Scholar
• Zukauskaite R, Hansen CR, Brink C, et al. Analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods. Acta Oncol. 2017;56(11):1554–1561. doi:10.1080/0284186X.2017.1346384.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346. doi:10.1016/0197-2456(96)00075-x.
   PubMedGoogle Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144.
   Web of Science ®Google Scholar
• Bol V, Grégoire V. Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers. Biomed Res Int. 2014;2014:696028. doi:10.1155/2014/696028.
   PubMed Web of Science ®Google Scholar
• Berwouts D, Olteanu LAM, Duprez F, et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. Radiother Oncol. 2013;107(3):310–316. doi:10.1016/j.radonc.2013.04.002.
   PubMed Web of Science ®Google Scholar
• Rasmussen JH, Håkansson K, Vogelius IR, et al. Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. Radiother Oncol. 2016;120(1):76–80. doi:10.1016/j.radonc.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60. doi:10.1016/S0140-6736(18)32752-1.
   PubMed Web of Science ®Google Scholar
• Burr AR, Harari PM, Ko HC, et al. Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer. Oral Oncol. 2019;92:52–56. doi:10.1016/j.oraloncology.2019.03.013.
   PubMed Web of Science ®Google Scholar